Baidu
map

Blood:维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增

2020-09-22 MedSci原创 MedSci原创

维甲酸主要增加同种异体反应性的RARahi CD8效应T细胞,包括体内鉴定的表型细胞。IL-23可通过选择性增加CD8效应T细胞上b7整合素的表达和降低具有调节细胞表型的CD4 T细胞来加强这一效应。

胃肠道(GI)移植物抗宿主病(GvHD)是异基因造血干细胞移植(AHST)的主要障碍。代谢产物维甲酸(RA)通过表达RA受体α(RARα)的同种反应性T细胞增强小鼠的GI-GvHD,但RA反应性细胞在人GI-GvHD中的作用尚不清楚。

在本研究中,Ball等使用传统的和新型序贯免疫染色和流式细胞术来仔细观察AHST患者组织和血液中的RA反应性T细胞,并表征RA对人类T细胞同种异体反应的影响。

(在GI-GvHD组织中,RARαhi单核细胞数量增多)

在RA暴露后,人单个核细胞RARα的表达水平增加。在GI-GvHD组织中,RARαhi单核细胞数量增多,这些细胞内的RA结合蛋白增多,定位于组织损伤的地方,与GvHD的严重程度和病死率相关。

(在GvHD组织中,T-bet的表达增多)

通过靶向候选蛋白方法,研究人员预测了在微环境IL-23增加的情况下RA反应性T细胞的表型。序贯免疫染色证实了存在一群具有预测表型的RARahi CD8T细胞,共表达效应T细胞转录因子T-bet和IL-23特异性受体。这些细胞在GI-GvHD组织中增加,但在皮肤-GvHD组织中没有增加,并且在GI-GvHD患者的血液中有选择性地扩增。

最后,功能研究显示,RA主要增加同种异体反应性的RARahi CD8效应T细胞,包括体内鉴定的表型细胞。富含IL-23的条件可通过选择性增加CD8效应T细胞上b7整合素的表达和降低具有调节细胞表型的CD4 T细胞来加强这一效应。

总之,Ball等鉴定出了一组具有独特表型的RA反应性效应T细胞,它们在人GI-GvHD中选择性扩增,可作为潜在的新的治疗靶点。

原始出处:

Ball Jennifer A,Clear Andrew James,Aries James et al. Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD. Blood, Sep 09 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-10-14 12513136m76(暂无昵称)

    学习了很不错,每天都要来学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-24 tomyang93
  7. [GetPortalCommentsPageByObjectIdResponse(id=2022850, encodeId=2f7d202285010, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Oct 02 20:42:37 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922966, encodeId=2e0d1922966a1, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Aug 12 06:42:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892089, encodeId=928a8920890e, content=学习了很不错,每天都要来学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201211/3bfec5fbc20b4196abdf11d80e7de414/8f53131a3a5e4e5caab63204a79128f2.jpg, createdBy=90402537000, createdName=12513136m76(暂无昵称), createdTime=Wed Oct 14 19:49:26 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479664, encodeId=955c14e9664af, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605406, encodeId=075716054065e, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Sep 24 05:42:37 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887436, encodeId=43e688e4366c, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80552210375, createdName=女医生, createdTime=Tue Sep 22 18:30:10 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-22 女医生

    学到了

    0

相关资讯

Gastroenterology:维甲酸和淋巴毒素信号可以促进人类肠道M细胞的分化

肠道微折叠(M)细胞是Peyer斑中肠道上皮细胞的独特亚型细胞,可调节粘膜免疫力,还可作为腔内抗原采样和摄取的第一道防线。但是目前的技术无法在细胞培养中有效培育人类M细胞。

痤疮治疗创新疗法Twyneo:达到了III期试验的主要终点

Sol-Gel Technologies近日宣布,其Twyneo(维甲酸和过氧化苯甲酰的组合)在两项治疗痤疮的III期临床试验中显著改善了所有主要终点。

Neurology:较低的血清维甲酸水平可预测较高死亡风险的缺血性卒中患者

由此可见,低循环RA水平与首发AIS患者队列中全因死亡和CVD死亡风险增加相关,这表明RA水平可能是独立于已知常规危险因素的预测因子。

J Clin Oncol:丙戊酸和维甲酸联合地西他滨治疗老年急性髓性白血病患者的效果

当前,有研究正在探究DNA-次甲基化药物与其他表观遗传学药物,如组蛋白去乙酰化酶抑制剂或分化诱导剂(如视黄醇)联合治疗骨髓瘤的效果。我们进行了一项2×2因子设计的随机II期试验,研究组蛋白

Circulation Research:血清维甲酸与冠状动脉疾病患者死亡率相关

在冠状动脉疾病患者中,血清维甲酸水平与患者死亡率相关

Baidu
map
Baidu
map
Baidu
map